Evidence map›Paper›PMID 39591188›Full record

ArticleVaccines2024

A Comprehensive Evaluation of the HPV Neutralizing Antibodies in Guangzhou, China: A Comparative Study on Various HPV Vaccines.

Renyun Zha, Conghui Liao, Daner Lin, Lixuan Zhao, Yanfang Chen, Lin Yao, Xiaokang Li, Boyang Yi, Ting Li, Jianpeng Xiao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Renyun ZhaSchool of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Conghui LiaoSchool of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Daner LinGuangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou 510445, China.
Lixuan ZhaoGuangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou 510445, China.
Yanfang ChenGuangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou 510445, China.
Lin YaoGuangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou 510445, China.
Xiaokang LiSchool of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Boyang YiTranslational Cancer Research Center, Peking University First Hospital, Beijing 100034, China.
Ting LiSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325000, China.
Jianpeng XiaoGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
Yan HuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Zeliang ChenSchool of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Cheng GuoSchool of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.ORCID 0000-0002-6602-8810
Jianyun LuGuangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou 510445, China.
Jiahai LuSchool of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.ORCID 0000-0002-8593-3402

Funding

grants from Discipline Cluster of Oncology, Wenzhou Medical University, China z1-2023005Guangdong Provincial Drug Administration Science and Technology Innovation Project 2023ZDZ07Guangzhou Health Science and Technology General Guidance Project 20241A010096National Key Research and Development Project 2018YFE0208000National Natural Science Foundation of China International (Regional) Cooperation and Exchange Project 2023YFVA1005
6 · The paper itself

Abstract

backgroundThe evaluation of HPV vaccine effectiveness is essential for informing public health strategies, yet there remains a gap in understanding humoral immune responses generated by different HPV vaccine formulations in regional populations. This study addresses this gap by evaluating the immunogenicity of the newly developed HPV vaccine Cecolin (Wantai), alongside various imported vaccines, including bivalent, quadrivalent, and nonavalent options available in China.

methodsFrom March 2023 to June 2024, a total of 352 participants were enrolled, including 87 females aged 9-14 years who received two doses of the bivalent HPV vaccine (Cecolin), 215 females aged 15-45 years who were fully vaccinated with various HPV vaccines, and 50 non-recipients. Follow-up assessments were conducted at six timepoints during the administration of Cecolin. Serum was collected at enrollment and at each follow-up visit for antibody assessments using a pseudovirion-based neutralization assay (PBNA).

findingsThe longitudinal follow-up of females aged 9-14 years revealed a 100% conversion rate for neutralizing antibodies against HPV types 16 and 18 after the second dose, compared to 94.3% and 97.1% conversion rates six months after the first dose. Compared to participants who received full doses of quadrivalent and nonavalent vaccines, females who received two or three doses of Cecolin exhibited higher neutralizing antibody geometric mean titers (GMTs) and non-vaccine-type (HPV31 and HPV33) antibody seroconversion rates.

interpretationThe domestically produced HPV vaccine Cecolin in China demonstrates strong immunogenicity and holds promise for the large-scale vaccination of females in developing countries to prevent cervical cancer.

Indexed as

HPV vaccineneutralizing antibodypseudovirionseroprevalence

Identifiers

PMID39591188
PMCPMC11599073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.